The complexity of gene- and cell-based therapies leads to similarly complex quality assurance requirements, well in excess of those expected for conventional small-molecule therapeutics, while expedited approval pathways demand earlier selection of the tools used for product manufacture. Dr. Roos, Strategic Alliances Leader for Cell Therapy at Thermo Fisher Scientific, reviewed the critical role of tool and technology development companies in supporting the translation of regenerative medical therapies.